{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:31:20Z","timestamp":1787905880354,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40257-022-00749-1","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T15:02:24Z","timestamp":1673362944000},"page":"153-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-9009","authenticated-orcid":false,"given":"Lauren","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nneka","family":"Comfere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayemi","family":"Sokumbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"issue":"2012","key":"749_CR1","first-page":"1","volume":"16","author":"AL Rodd","year":"2012","unstructured":"Rodd AL, Ververis K, Karagiannis TC. Current and emerging therapeutics for cutaneous T-cell lymphoma: histone deacetylase inhibitors. Lymphoma. 2012;16(2012):1\u201310.","journal-title":"Lymphoma"},{"issue":"S1","key":"749_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hon.2850","volume":"39","author":"W Kempf","year":"2021","unstructured":"Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas\u2014an update 2021. Hematol Oncol. 2021;39(S1):46\u201351.","journal-title":"Hematol Oncol"},{"issue":"308","key":"749_CR3","doi-asserted-by":"publisher","first-page":"308ra158","DOI":"10.1126\/scitranslmed.aaa9122","volume":"7","author":"IR Kirsch","year":"2015","unstructured":"Kirsch IR, Watanabe R, O\u2019Malley JT, Williamson DW, Scott L, Elco CP, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308):308ra158.","journal-title":"Sci Transl Med."},{"issue":"4","key":"749_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.det.2019.05.007","volume":"37","author":"E Peterson","year":"2019","unstructured":"Peterson E, Weed J, Lo Sicco K, Latkowski JA. Cutaneous T cell lymphoma: a difficult diagnosis demystified. Dermatol Clin. 2019;37(4):455\u201369.","journal-title":"Dermatol Clin"},{"issue":"308","key":"749_CR5","doi-asserted-by":"publisher","first-page":"308fs41","DOI":"10.1126\/scitranslmed.aad2518","volume":"7","author":"J Weed","year":"2015","unstructured":"Weed J, Girardi M. The difficult\u2013and often delayed\u2013diagnosis of CTCL. Sci Transl Med. 2015;7(308):308fs41.","journal-title":"Sci Transl Med."},{"key":"749_CR6","doi-asserted-by":"crossref","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term Outcome of 525 Patients With Mycosis Fungoides and S\u00e9zary Syndrome. Arch Dermatol. 2003;139(7).","DOI":"10.1001\/archderm.139.7.857"},{"issue":"3","key":"749_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2006.09.016","volume":"56","author":"A Lozano","year":"2007","unstructured":"Lozano A, Duvic M. Cutaneous T-cell lymphoma in non-blood-related family members: report of an additional case. J Am Acad Dermatol. 2007;56(3):521.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"749_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000251078","volume":"154","author":"PG Hazen","year":"1977","unstructured":"Hazen PG, Michel B. Hodgkin\u2019s disease and mycosis fungoides in a married couple. Dermatologica. 1977;154(5):257\u201360.","journal-title":"Dermatologica"},{"issue":"5","key":"749_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jaad.2013.11.054","volume":"71","author":"I Triantafyllopoulou","year":"2014","unstructured":"Triantafyllopoulou I, Nikolaou V, Marinos L, Papadaki T, Antoniou C. Tumor stage mycosis fungoides in nonblood-related family members. J Am Acad Dermatol. 2014;71(5):1001\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"749_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/01.jom.0000194160.95468.20","volume":"48","author":"MM Morales-Su\u00e1rez-Varela","year":"2006","unstructured":"Morales-Su\u00e1rez-Varela MM, Olsen J, Johansen P, Kaerlev L, Gu\u00e9nel P, Arveux P, et al. Occupational sun exposure and mycosis fungoides: a European multicenter case-control study. J Occup Environ Med. 2006;48(4):390\u20133.","journal-title":"J Occup Environ Med"},{"issue":"3","key":"749_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4103\/0019-5154.156423","volume":"60","author":"N Meibodi","year":"2015","unstructured":"Meibodi N, Ghazvini K, Esmaily H, Hesamifard M, Nahidi Y. Evaluation of the association between epstein-barr virus and mycosis fungoides. Indian J Dermatol. 2015;60(3):321.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"749_CR12","first-page":"212","volume":"136","author":"O Jumbou","year":"1997","unstructured":"Jumbou O, Mollat C, N\u2019Guyen JM, Billaudel S, Litoux P, Dr\u00e9no B. Increased anti-Epstein-Barr virus antibodies in epidermotropic cutaneous T-cell lymphoma: a study of 64 patients. Br J Dermatol. 1997;136(2):212\u20136.","journal-title":"Br J Dermatol"},{"issue":"6","key":"749_CR13","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2002-07-2247","volume":"101","author":"KL Herne","year":"2003","unstructured":"Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and S\u00e9zary syndrome. Blood. 2003;101(6):2132\u20136.","journal-title":"Blood"},{"issue":"5 Suppl","key":"749_CR14","doi-asserted-by":"publisher","first-page":"S202","DOI":"10.1016\/j.jaad.2005.09.013","volume":"54","author":"AN Schmidt","year":"2006","unstructured":"Schmidt AN, Robbins JB, Greer JP, Zic JA. Conjugal transformed mycosis fungoides: the unknown role of viral infection and environmental exposures in the development of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;54(5 Suppl):S202\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"749_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/1523-1747.ep12363352","volume":"107","author":"CM Jackow","year":"1996","unstructured":"Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol. 1996;107(3):373\u20136.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"749_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/cncr.27740","volume":"119","author":"RR Jahan-Tigh","year":"2013","unstructured":"Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer. 2013;119(4):825\u201331.","journal-title":"Cancer"},{"issue":"10","key":"749_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1159\/000509281","volume":"181","author":"M Bobrowicz","year":"2020","unstructured":"Bobrowicz M, Fassnacht C, Ignatova D, Chang Y, Dimitriou F, Guenova E. Pathogenesis and therapy of primary cutaneous T-cell lymphoma: collegium internationale allergologicum (CIA) upd ate 2020. Int Arch Allergy Immunol. 2020;181(10):733\u201345.","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"749_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajh.24233","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151\u201365.","journal-title":"Am J Hematol"},{"issue":"12","key":"749_CR19","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/ng.3442","volume":"47","author":"AC da Silva Almeida","year":"2015","unstructured":"da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen CP, et al. The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome. Nat Genet. 2015;47(12):1465\u201370.","journal-title":"Nat Genet"},{"issue":"9","key":"749_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","volume":"47","author":"J Choi","year":"2015","unstructured":"Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011\u20139.","journal-title":"Nat Genet"},{"issue":"12","key":"749_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/gcc.22679","volume":"57","author":"AN Bastidas Torres","year":"2018","unstructured":"Bastidas Torres AN, Cats D, Mei H, Szuhai K, Willemze R, Vermeer MH, et al. Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides. Genes Chromosomes Cancer. 2018;57(12):653\u201364.","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"749_CR22","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","volume":"130","author":"J Park","year":"2017","unstructured":"Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood. 2017;130(12):1430\u201340.","journal-title":"Blood"},{"issue":"5","key":"749_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clml.2012.06.010","volume":"12","author":"LD Wilson","year":"2012","unstructured":"Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12(5):291\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"749_CR24","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jaad.2017.12.068","volume":"78","author":"ME Martinez-Escala","year":"2018","unstructured":"Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"749_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2008.10.060","volume":"61","author":"A Moustou","year":"2009","unstructured":"Moustou A, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti\u2013tumor necrosis factor biologic therapy: A clinical review. J Am Acad Dermatol. 2009;61(3):486\u2013504.","journal-title":"J Am Acad Dermatol"},{"key":"749_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jdcr.2021.05.037","volume":"14","author":"NA Trum","year":"2021","unstructured":"Trum NA, Zain J, Abad C, Rosen ST, Querfeld C. Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash. JAAD Case Reports. 2021;14:37\u201342.","journal-title":"JAAD Case Reports."},{"issue":"6","key":"749_CR27","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/jdv.17001","volume":"35","author":"O Steck","year":"2021","unstructured":"Steck O, Bertschi NL, Luther F, van den Berg J, Winkel DJ, Holbro A, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with S\u00e9zary syndrome. J Eur Acad Dermatol Venereol. 2021;35(6):1331\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"749_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1046\/j.1365-2133.2003.05384.x","volume":"149","author":"E Mah\u00e9","year":"2003","unstructured":"Mah\u00e9 E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003;149(1):170\u20133.","journal-title":"Br J Dermatol"},{"issue":"4","key":"749_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jaad.2004.03.047","volume":"51","author":"AE Adams","year":"2004","unstructured":"Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol. 2004;51(4):660\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"749_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2133.2005.06686.x","volume":"153","author":"S Dalle","year":"2005","unstructured":"Dalle S, Balme B, Berger F, Hayette S, Thomas L. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol. 2005;153(1):207\u20138.","journal-title":"Br J Dermatol"},{"issue":"4","key":"749_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3816\/CLM.2006.n.008","volume":"6","author":"C Berthelot","year":"2006","unstructured":"Berthelot C, Cather J, Jones D, Duvic M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma. 2006;6(4):329\u201332.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"749_CR32","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1365-2133.2006.07713.x","volume":"156","author":"J Dauendorffer","year":"2007","unstructured":"Dauendorffer J, Rivet J, Allard A, Bachelez H. S\u00e9zary syndrome in a patient receiving infliximab for ankylosing spondylitis. Br J Dermatol. 2007;156(4):742\u20133.","journal-title":"Br J Dermatol"},{"issue":"6","key":"749_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2340\/00015555-0728","volume":"89","author":"L Koens","year":"2009","unstructured":"Koens L, Senff NJ, Vermeer MH, Ronday HK, Willemze R, Jansen PM. Cutaneous gamma\/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis. Acta Derm Venereol. 2009;89(6):653\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"749_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archdermatol.2008.526","volume":"145","author":"P Lafaille","year":"2009","unstructured":"Lafaille P, Bouffard D, Provost N. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol. 2009;145(1):78.","journal-title":"Arch Dermatol"},{"issue":"3","key":"749_CR35","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1365-2036.2008.03882.x","volume":"29","author":"CW Lees","year":"2009","unstructured":"Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29(3):286\u201397.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"749_CR36","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1365-2133.2009.09044.x","volume":"160","author":"C Michot","year":"2009","unstructured":"Michot C, Costes V, Gerard-Dran D, Guillot B, Combes B, Dereure O. Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. Br J Dermatol. 2009;160(4):889\u201390.","journal-title":"Br J Dermatol"},{"issue":"2","key":"749_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jcv.2013.07.011","volume":"58","author":"AL Bittencourt","year":"2013","unstructured":"Bittencourt AL, Oliveira PD, Bittencourt VG, Carvalho EM, Farre L. Adult T-cell leukemia\/lymphoma triggered by adalimumab. J Clin Virol. 2013;58(2):494\u20136.","journal-title":"J Clin Virol"},{"issue":"4","key":"749_CR38","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"K Papp","year":"2013","unstructured":"Papp K, Griffiths C, Gordon K, Lebwohl M, Szapary P, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844\u201354.","journal-title":"Br J Dermatol"},{"issue":"3","key":"749_CR39","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1016\/j.jaad.2014.03.022","volume":"71","author":"SM Jacks","year":"2014","unstructured":"Jacks SM, Taylor BR, Rogers RP, Ralston JS, Metcalf JS, Lazarchick J. Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti\u2019) lymphoma after administration of adalimumab. J Am Acad Dermatol. 2014;71(3):e86\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"749_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2340\/00015555-1675","volume":"94","author":"H Suga","year":"2014","unstructured":"Suga H, Sugaya M, Toyama T, Sumida H, Fujita H, Kogure A, et al. A case of mycosis fungoides with large cell transformation associated with infliximab treatment. Acta Derm Venereol. 2014;94(2):233\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"749_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1590\/abd1806-4841.20163875","volume":"91","author":"H Ma","year":"2016","unstructured":"Ma H, Qiu S, Lu R, Feng P, Lu C. Methotrexate and etanercept-induced primary cutaneous CD4 positive small\/medium-sized pleomorphic T-cell lymphoma. An Bras Dermatol. 2016;91(3):368\u201371.","journal-title":"An Bras Dermatol"},{"key":"749_CR42","doi-asserted-by":"crossref","unstructured":"D\u02bcHaens G, Reinisch W, Panaccione R, Satsangi J, Petersson J, Bereswill M, et al. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry. Am J Gastroenterol. 2018 06;113(6):872-82.","DOI":"10.1038\/s41395-018-0098-4"},{"issue":"9","key":"749_CR43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2340\/00015555-3208","volume":"99","author":"T Chiba","year":"2019","unstructured":"Chiba T, Nagai T, Osada SI, Manabe M. Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis. Acta Derm Venereol. 2019;99(9):818\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"749_CR44","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1111\/ijd.14367","volume":"58","author":"F Partarrieu-Mej\u00edas","year":"2019","unstructured":"Partarrieu-Mej\u00edas F, D\u00edaz-Corpas T, P\u00e9rez-Ferriols A, Alegre-de MV. Mycosis fungoides after treatment with tumor necrosis factor-alpha inhibitors for psoriasis: progression or onset. Int J Dermatol. 2019;58(5):e103\u20135.","journal-title":"Int J Dermatol"},{"issue":"1","key":"749_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","volume":"83","author":"ML Espinosa","year":"2020","unstructured":"Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, Pontes DS, Silverberg JI, Choi J, Pro B, Pincus LB, Guitart J, Zhou XA. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.050. (Epub 2020 Mar 27. PMID: 32229275; PMCID: PMC7302979).","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"749_CR46","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.12788\/cutis.0074","volume":"106","author":"LC Hollins","year":"2020","unstructured":"Hollins LC, Wirth P, Fulchiero GJ, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020;106(2):E8\u201311.","journal-title":"Cutis"},{"issue":"6","key":"749_CR47","doi-asserted-by":"publisher","first-page":"e13880","DOI":"10.1111\/dth.13880","volume":"33","author":"D Miyashiro","year":"2020","unstructured":"Miyashiro D, Vivarelli AG, Gon\u00e7alves F, Cury-Martins J, Sanches JA. Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther. 2020;33(6):e13880.","journal-title":"Dermatol Ther"},{"key":"749_CR48","doi-asserted-by":"crossref","unstructured":"Tran J, Morris L, Vu A, Duvic M. Development of S\u00e9zary syndrome following the administration of dupilumab. Dermatol Online J. 2020;26(4):13030\/qt1m67z8sb.","DOI":"10.5070\/D3264048364"},{"key":"749_CR49","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001875","author":"O Sokumbi","year":"2021","unstructured":"Sokumbi O, Shamim H, Davis M, Wetter D, Newman C, Comfere N. Evolution of dupilumab-associated cutaneous atypical lymphoid infiltrates. Am J Dermatopathol. 2021. https:\/\/doi.org\/10.1097\/DAD.0000000000001875. ([published online: June 15, 2021]).","journal-title":"Am J Dermatopathol"},{"issue":"1S","key":"749_CR50","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1097\/DER.0000000000000679","volume":"32","author":"M Ayasse","year":"2021","unstructured":"Ayasse M, Nelson K, et al. Mycosis fungoides unmasked by dupilumab treatment in a patient with a history of atopic dermatitis. Dermatitis. 2021;32(1S):e88\u20139.","journal-title":"Dermatitis"},{"key":"749_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jdcr.2021.09.020","volume":"18","author":"A Du-Thanh","year":"2021","unstructured":"Du-Thanh A, Gustave V, et al. Lethal anaplastic large-cell lymphoma occurring in a patient treated with dupilumab. JAAD Case Rep. 2021;18:4\u20137.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"749_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5070\/D3271052041","volume":"27","author":"M Newsom","year":"2021","unstructured":"Newsom M, Hrin ML, et al. Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab. Dermatol Online J. 2021;27(1):15.","journal-title":"Dermatol Online J"},{"key":"749_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","volume":"8","author":"K Russomanno","year":"2021","unstructured":"Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2021;8:83\u20135.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"749_CR54","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12328-020-01277-3","volume":"14","author":"T Yasuda","year":"2021","unstructured":"Yasuda T, Takagi T, et al. Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy. Clin J Gastroenterol. 2021;14(1):170\u20135.","journal-title":"Clin J Gastroenterol"},{"issue":"3","key":"749_CR55","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/1078-0432.CCR-07-0610","volume":"14","author":"BF Chong","year":"2008","unstructured":"Chong BF, Wilson AJ, Gibson HM, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma\/mycosis fungoides. Clin Cancer Res. 2008;14(3):646\u201353.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"749_CR56","doi-asserted-by":"publisher","first-page":"953","DOI":"10.5114\/ada.2021.107553","volume":"38","author":"K Ko\u0142kowski","year":"2021","unstructured":"Ko\u0142kowski K, Soko\u0142owska-Wojdy\u0142o M. Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL). Postepy Dermatologii i Alergologii. 2021;38(6):953\u201360.","journal-title":"Postepy Dermatologii i Alergologii"},{"issue":"24","key":"749_CR57","doi-asserted-by":"publisher","first-page":"13388","DOI":"10.3390\/ijms222413388","volume":"22","author":"K Ko\u0142kowski","year":"2021","unstructured":"Ko\u0142kowski K, et al. Safety and danger considerations of novel treatments for atopic dermatitis in context of primary cutaneous lymphomas. Int J Mol Sci. 2021;22(24):13388.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"749_CR58","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2020.12.026","volume":"84","author":"DM Weiner","year":"2021","unstructured":"Weiner DM, et al. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: current and future approaches. J Am Acad Dermatol. 2021;84(3):597\u2013604.","journal-title":"J Am Acad Dermatol"},{"key":"749_CR59","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3389\/fonc.2019.00300","volume":"9","author":"FM Ghazawi","year":"2019","unstructured":"Ghazawi FM, Alghazawi N, Le M, Netchiporouk E, Glassman SJ, Sasseville D, et al. Environmental and other extrinsic risk factors contributing to the pathogenesis of cutaneous T cell lymphoma (CTCL). Front Oncol. 2019;9:300.","journal-title":"Front Oncol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00749-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00749-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00749-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T01:17:58Z","timestamp":1677287878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00749-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00749-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"5 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LS wrote the manuscript, collected,\u00a0and analyzed data for Table 1. OS and NK\u00a0contributed\u00a0substantial efforts\u00a0to the\u00a0conception and design as well as the acquisition and interpretation\u00a0of data. All authors reviewed the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Lauren Schaefer, Nneka Comfere, and Olayemi Sokumbi declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Reviewed and approved by Mayo Clinic IRB.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval status"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}